MacroGenics Inc (MGNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.40+3.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MGNX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain financial stability with pro forma cash and partner payments supporting operations through 2028.
Stated as a priority in 3 of last 3 quarters. Pro forma cash, cash equivalents and marketable securities increased from $154.2 million in 2026-Q1 to $327 million in 2026-Q2, supported by proceeds from manufacturing divestiture and partner payments. Management has consistently extended cash runway guidance through 2028, delivering on this financial stability priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“pro forma cash, cash equivalents and marketable securities of $327 million as of June 30, 2026, plus other projected future payments from partners, will support the Company’s cash runway through 2028”
“Cash runway guidance extended through 2028, based on anticipated closing of manufacturing divestiture”
“cash runway guidance remains into late 2027”
Complete sale of GMP manufacturing operations and transition to fully outsourced manufacturing model to increase focus and agility.
Stated as a priority in 3 of last 3 quarters. The sale of GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million was completed in 2026-Q2, with approximately 140 employees transferring to Bora. Management transitioned to a fully outsourced manufacturing model, delivering on this strategic focus shift.
“Announced sale of manufacturing operations for $122.5 million and transition to fully outsourced model”
“Entered into definitive agreement to sell manufacturing operations to Bora Pharmaceuticals for $122.5 million”
“Cash runway guidance remains into late 2027, prior to divestiture announcement”
Earn up to $20 million contingent milestone payment based on 2026 net sales thresholds of ZYNYZ.
Stated as a priority in 2 of last 2 quarters. Management reiterated eligibility for a $20 million milestone payment contingent on 2026 ZYNYZ net sales. Revenue from royalty and collaborative agreements increased from $20.8 million in 2026-Q1 to $32.8 million in 2026-Q2, indicating progress toward milestone achievement.
“Eligible to receive an additional one-time milestone payment of up to $20.0 million contingent upon ZYNYZ achieving specified 2026 net sales thresholds”
“Potential to receive an additional milestone of up to $20.0 million based on 2026 ZYNYZ sales performance”
Progress clinical development of MGC026, MGC028, MGC030 ADCs and lorigerlimab TCE with upcoming data presentations and IND filings.
Stated as a priority in 3 of last 3 quarters. Management has advanced clinical programs including MGC026, MGC028, MGC030 ADCs and lorigerlimab TCE with ongoing Phase 1 and 2 studies and planned data presentations at ESMO 2026. The IND for MGC030 was cleared ahead of schedule, indicating progress in pipeline development.
“Data presentations at ESMO planned for MGC026 and lorigerlimab; MGC028 dose escalation ongoing; MGC030 IND cleared ahead of schedule”
“ADC pipeline remains on track for multiple data disclosures and program milestones”
“Advancing pipeline with clinical and preclinical ADC and TCE programs”
Reduce workforce to approximately 140 employees post-manufacturing divestiture to create a leaner, more agile organization.
Stated as a priority in 2 of last 2 quarters. Management has executed workforce reduction aligned with manufacturing divestiture, transferring approximately 140 employees to Bora and targeting a leaner organization of about 140 employees focused on drug development, delivering on restructuring goals.
“Workforce anticipated to be reduced to approximately 140 employees by year-end following restructuring and divestiture”
“Approximately 140 employees expected to transfer to Bora; company to have about 135 employees post-closing”
Over the trailing year it converted 0.94x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
13 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.